Want to see TSE:NEVI full AI Analyst Report?
NEVI Stock Chart & Stats
C$0.02
C$0.00(0.00%)
At close: 4:00 PM EDT
C$0.02
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.02 - C$0.10
Previous CloseN/A
Volume20.00K
Average Volume (3M)55.49K
Market Cap
C$793.25K
Enterprise ValueC$1.32
Total Cash (Recent Filing)C$60.85K
Total Debt (Recent Filing)C$394.63K
Price to Earnings (P/E)―
Beta1.75
Next Earnings
Oct 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding39,662,727
10 Day Avg. Volume84,932
30 Day Avg. Volume55,489
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)2.05
Price to Sales (P/S)1.17
P/FCF Ratio31.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Gross Margin ImprovementGross margin roughly doubled to ~41% TTM from ~23% in the prior annual period, reflecting improved unit economics or better pricing/mix. Sustained higher gross margins support durable profitability and operating leverage as revenue stabilizes, improving long-term cash generation.
Positive Operating & Free Cash FlowOperating and free cash flow have turned positive on a trailing twelve‑month basis, showing the business can generate cash despite prior losses. Positive FCF provides management flexibility to fund operations, reduce external financing needs, and invest in strategic initiatives over months.
Improved Balance Sheet StabilityEquity is positive and leverage is modest (debt-to-equity ~0.25), indicating a materially improved balance sheet versus earlier years. This lowers refinancing and solvency risk, giving the company time to execute turnaround measures and sustain operations during a multi‑month recovery.
Bears Say
Contracting RevenueTop-line is contracting sharply (growth rate ~-1.146) with modest scale (TTM revenue ~1.66M). Persistent revenue decline undermines fixed-cost absorption, weakens long-term margin sustainability, and makes the recent margin and cash improvements fragile unless revenue stabilizes or reverses.
Persistent Net LossesThe company remains loss-making with negative operating profit and TTM net income around -0.35M. Continued losses erode retained equity and reduce internal funding for growth, meaning the business needs sustained operational improvement to reach durable break-even and preserve capital.
Fragile Cash Growth & ConversionAlthough FCF is positive, free cash flow growth is negative (-10.727) and cash conversion remains modest (~0.083). Weak FCF momentum limits the firm's ability to invest, pay down debt, or absorb shocks, making long-term recovery dependent on consistent improvement in both revenue and margins.
Pascal Biosciences Inc News
NEVI FAQ
What was Pascal Biosciences Inc’s price range in the past 12 months?
Pascal Biosciences Inc lowest stock price was C$0.02 and its highest was C$0.10 in the past 12 months.
What is Pascal Biosciences Inc’s market cap?
Pascal Biosciences Inc’s market cap is C$793.25K.
When is Pascal Biosciences Inc’s upcoming earnings report date?
Pascal Biosciences Inc’s upcoming earnings report date is Oct 16, 2026 which is in 61 days.
How were Pascal Biosciences Inc’s earnings last quarter?
Pascal Biosciences Inc released its earnings results on Jul 16, 2026. The company reported -C$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Pascal Biosciences Inc overvalued?
According to Wall Street analysts Pascal Biosciences Inc’s price is currently Overvalued.
Does Pascal Biosciences Inc pay dividends?
Pascal Biosciences Inc does not currently pay dividends.
What is Pascal Biosciences Inc’s EPS estimate?
Pascal Biosciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pascal Biosciences Inc have?
Pascal Biosciences Inc has 39,662,727 shares outstanding.
What happened to Pascal Biosciences Inc’s price movement after its last earnings report?
Pascal Biosciences Inc reported an EPS of -C$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Pascal Biosciences Inc?
Currently, no hedge funds are holding shares in TSE:NEVI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pascal Biosciences Inc
Nevis Brands Inc. engages in the development and sale of cannabis products in the United States. It offers hemp derived THC beverages under the Major brand name. The company was formerly known as Pascal Biosciences Inc. and changed its name to Nevis Brands Inc. in June 2023. Nevis Brands Inc. is headquartered in Seattle, Washington.
Technical Analysis
TAAT Global Alternatives
―
―
Modern Meat
―
Lifeist Wellness
―
Element Nutritional Sciences Inc
―